According to the company, in the Phase 3 RASolute 302 trial, daraxonrasib showed a roughly 60 per cent reduction in the risk of death and a doubling of median overall survival compared with standard second-line chemotherapy. …
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 19 June
June 19, 2026 - - Podcast -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News